Comparative effectiveness of peroxisome proliferator–activated receptor agonists as second-line therapies for primary biliary cholangitis: A systematic review and network meta-analysis

医学 小学(天文学) 生物信息学 兴奋剂 药品 药理学 受体 排名(信息检索) 原发性胆汁性肝硬化 过氧化物酶体增殖物激活受体 内科学 PPAR激动剂 梅德林 过氧化物酶体增殖物 临床试验 计算生物学 药物开发 药物发现
作者
Adrielly Martins,Nidah Shabbir Khakoo,Anish Reddy,John M. Reynolds,Christophe Corpechot,Alexandra Rousseau,Mohammed Murad,Shahnaz Sultan,Cynthia Levy
出处
期刊:Hepatology [Lippincott Williams & Wilkins]
卷期号:83 (4): 721-734 被引量:12
标识
DOI:10.1097/hep.0000000000001465
摘要

BACKGROUND AND AIMS: Primary biliary cholangitis is a chronic cholestatic liver disease that may progress to cirrhosis and liver failure. For patients with inadequate response or intolerance to ursodeoxycholic acid, peroxisome proliferator-activated receptor (PPAR) agonists have emerged as second-line options. This study assessed the comparative effectiveness and safety of PPAR agonists in primary biliary cholangitis through a systematic review and network meta-analysis. APPROACH AND RESULTS: A systematic review identified randomized controlled trials evaluating PPAR agonists versus ursodeoxycholic acid, with or without placebo. A frequentist network meta-analysis assessed biochemical response (primary outcome) and ALP normalization (secondary outcome). Pairwise meta-analyses were performed for percentage change in ALP and total bilirubin, and adverse events leading to treatment discontinuation. Data were stratified by baseline ALP, and a random-effects model was used. Eight randomized controlled trials (727 participants) evaluating 4 PPAR agonists were included. All agents outperformed placebo in achieving biochemical response and ALP normalization. Bezafibrate ranked highest for the primary outcome; both bezafibrate and seladelpar ranked highest for the secondary outcome. Percentage ALP reduction did not vary by baseline ALP. Total bilirubin changes were similar across arms, and treatment discontinuations due to adverse events were infrequent. CONCLUSIONS: PPAR agonists are effective second-line therapies for primary biliary cholangitis. Treatment ranking differences likely reflect variations in outcomes, populations, and drug mechanisms. In the absence of head-to-head trials, network meta-analysis provides important insights into comparative effectiveness. Further studies are warranted to confirm long-term safety and improve the evaluation of patient-centered outcomes.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
碎觉觉发布了新的文献求助30
刚刚
1秒前
zhongchengcs完成签到,获得积分10
1秒前
1秒前
秋风的应助被xxxxxxzz采纳,获得10
1秒前
1秒前
1秒前
1秒前
2秒前
pan发布了新的文献求助10
2秒前
Chambray发布了新的文献求助10
2秒前
虎杖悠仁完成签到,获得积分20
2秒前
ccc完成签到,获得积分20
2秒前
章绝施完成签到,获得积分10
2秒前
3秒前
秋秋发布了新的文献求助10
4秒前
4秒前
大话家完成签到,获得积分10
4秒前
雨小葵发布了新的文献求助20
4秒前
科目三的应助被山东科技李采纳,获得10
5秒前
打打的应助被小航2025采纳,获得10
5秒前
天天开心发布了新的文献求助10
5秒前
ccc发布了新的文献求助10
5秒前
jst完成签到,获得积分10
6秒前
6秒前
漫步海滩发布了新的文献求助10
6秒前
7秒前
ZRui发布了新的文献求助10
7秒前
2Q发布了新的文献求助10
7秒前
8秒前
8秒前
顺顺利利发布了新的文献求助10
9秒前
恩雁发布了新的文献求助10
10秒前
完美世界的应助被科研通管家采纳,获得10
10秒前
Owen的应助被科研通管家采纳,获得10
10秒前
10秒前
大模型的应助被科研通管家采纳,获得10
10秒前
糖果悠悠的应助被科研通管家采纳,获得10
10秒前
天天开心完成签到,获得积分10
10秒前
上官若男的应助被科研通管家采纳,获得10
10秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
plantTFDB 508
Resource Recovery Handbook 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8175943
求助须知:如何正确求助?哪些是违规求助? 9567501
关于积分的说明 21793186
捐赠科研通 7770490
什么是DOI,文献DOI怎么找? 3431935
关于科研通互助平台的介绍 2556294
邀请新用户注册赠送积分活动 2477485